IRIS
Cao, Davide
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 2.563
AS - Asia 2.126
EU - Europa 703
SA - Sud America 352
AF - Africa 50
OC - Oceania 5
Totale 5.799
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.493
SG - Singapore 1.217
CN - Cina 485
BR - Brasile 300
DE - Germania 192
VN - Vietnam 191
FI - Finlandia 149
IE - Irlanda 79
IT - Italia 77
IN - India 50
FR - Francia 48
GB - Regno Unito 44
HK - Hong Kong 41
SE - Svezia 41
CA - Canada 30
MX - Messico 24
IQ - Iraq 23
BD - Bangladesh 22
AR - Argentina 20
PL - Polonia 13
RU - Federazione Russa 13
JP - Giappone 12
ZA - Sudafrica 12
TR - Turchia 11
EG - Egitto 10
ES - Italia 10
NG - Nigeria 10
PK - Pakistan 10
NL - Olanda 9
ID - Indonesia 8
MA - Marocco 7
CO - Colombia 6
PY - Paraguay 6
UA - Ucraina 6
VE - Venezuela 6
EC - Ecuador 5
MY - Malesia 5
NP - Nepal 5
SA - Arabia Saudita 5
TH - Thailandia 5
AU - Australia 4
AZ - Azerbaigian 4
BE - Belgio 4
JO - Giordania 4
KZ - Kazakistan 4
UZ - Uzbekistan 4
AL - Albania 3
CL - Cile 3
CU - Cuba 3
JM - Giamaica 3
KE - Kenya 3
PE - Perù 3
PH - Filippine 3
PT - Portogallo 3
AE - Emirati Arabi Uniti 2
AF - Afghanistan, Repubblica islamica di 2
BB - Barbados 2
BO - Bolivia 2
CR - Costa Rica 2
DZ - Algeria 2
EE - Estonia 2
IL - Israele 2
LB - Libano 2
LT - Lituania 2
SY - Repubblica araba siriana 2
TN - Tunisia 2
TT - Trinidad e Tobago 2
AT - Austria 1
BH - Bahrain 1
CH - Svizzera 1
CI - Costa d'Avorio 1
CY - Cipro 1
CZ - Repubblica Ceca 1
DO - Repubblica Dominicana 1
GD - Grenada 1
GR - Grecia 1
IM - Isola di Man 1
IR - Iran 1
KW - Kuwait 1
LU - Lussemburgo 1
MN - Mongolia 1
NI - Nicaragua 1
NZ - Nuova Zelanda 1
OM - Oman 1
PA - Panama 1
RO - Romania 1
RS - Serbia 1
SN - Senegal 1
TG - Togo 1
TW - Taiwan 1
UG - Uganda 1
UY - Uruguay 1
Totale 5.799
Salva come PNG Salva come JPEG
Città #
Dallas 571
Singapore 520
San Jose 327
Ashburn 321
The Dalles 209
Shanghai 179
Helsinki 148
Beijing 145
Falkenstein 128
Boardman 104
Chandler 90
New York 90
Dublin 78
Ho Chi Minh City 66
Los Angeles 51
Wilmington 48
Hanoi 45
Hong Kong 39
Milan 33
Santa Clara 30
São Paulo 27
San Mateo 24
Pune 19
Ann Arbor 17
Seattle 14
Buffalo 13
Assago 12
Stockholm 12
Brooklyn 11
Warsaw 11
Benin City 10
Chicago 10
Lawrence 10
Mexico City 10
Montreal 10
Munich 10
Princeton 10
Council Bluffs 9
Leawood 9
Paris 9
Phoenix 9
Rio de Janeiro 9
Curitiba 8
Da Nang 8
Lauterbourg 8
London 8
Porto Alegre 8
Baghdad 7
Orem 7
San Francisco 7
Tokyo 7
Amsterdam 6
Denver 6
Fairfield 6
Haiphong 6
Naples 6
Abbiategrasso 5
Belo Horizonte 5
Biên Hòa 5
Dhaka 5
Düsseldorf 5
Frankfurt am Main 5
Johannesburg 5
New Delhi 5
Reston 5
Santo André 5
Toronto 5
Asunción 4
Boston 4
Brasília 4
Brussels 4
Campinas 4
Charlotte 4
Manchester 4
Mumbai 4
Shijiazhuang 4
Tashkent 4
Thái Bình 4
Woodbridge 4
Al Fayyum 3
Amman 3
Ankara 3
Atlanta 3
Betim 3
Bắc Giang 3
Caxias do Sul 3
Changsha 3
Chennai 3
Columbus 3
Erbil 3
Goiânia 3
Havana 3
Istanbul 3
Karachi 3
Kingston 3
Kuala Lumpur 3
Marseille 3
Moscow 3
Nairobi 3
Philadelphia 3
Totale 3.761
Salva come PNG Salva come JPEG
Nome #
1- Versus 3-Month DAPT in Older Patients at a High Bleeding Risk Undergoing PCI: Insights from the XIENCE Short DAPT Global Program 649
Direct oral anticoagulants in addition to antiplatelet therapy for secondary prevention after acute coronary syndromes: an updated systematic review and meta-analysis 140
Monotherapy with a P2Y12 inhibitor or aspirin for secondary prevention in patients with established atherosclerosis: a systematic review and meta-analysis. 136
On the Modeling of Patient-Specific Transcatheter Aortic Valve Replacement: A Fluid–Structure Interaction Approach 94
The synergy stent in high-bleeding risk patients: why design matters 83
Clinical Outcomes and Revascularization Strategies in Patients With Low-Flow, Low-Gradient Severe Aortic Valve Stenosis According to the Assigned Treatment Modality 83
Coronary Artery Disease Severity and Aortic Stenosis: Clinical Outcomes According to SYNTAX-Score in Patients Undergoing Transcatheter Aortic Valve Implantation 82
Design and rationale of the XIENCE short DAPT clinical program: An assessment of the safety of 3-month and 1-month DAPT in patients at high bleeding risk undergoing PCI with an everolimus-eluting stent 74
A contemporary simple risk score for prediction of contrast-associated acute kidney injury after percutaneous coronary intervention: derivation and validation from an observational registry 70
Impact of High-Density Lipoprotein Levels on Cardiovascular Outcomes of Patients Undergoing Percutaneous Coronary Intervention With Drug-Eluting Stents 70
Coronary Revascularisation in Transcatheter Aortic Valve Implantation Candidates: Why, Who, When? 68
Short Versus Long Duration of DAPT After DES Implantation: A Meta-Analysis. 67
Device profile of the Resolute Onyx Zotarolimus eluting coronary stent system for the treatment of coronary artery disease: overview of its safety and efficacy 66
Contrast-induced acute kidney injury 65
Ticagrelor monotherapy in patients at high bleeding risk undergoing percutaneous coronary intervention: TWILIGHT-HBR 63
Aspirin-free strategies: a framework to reassess the role of dual antiplatelet therapy after percutaneous coronary intervention 62
Impact of Race/Ethnicity on Long Term Outcomes After Percutaneous Coronary Intervention with Drug-Eluting Stents 61
Radial versus femoral access for coronary interventions: An updated systematic review and meta-analysis of randomized trials 61
Comparative influence of bleeding and ischemic risk factors on diabetic patients undergoing percutaneous coronary intervention with everolimus-eluting stents 61
Evolution of antithrombotic therapy in patients undergoing percutaneous coronary intervention: a 40-year journey 60
Depression and ischemic heart disease 60
Non-cardiac surgery in patients with coronary artery disease: risk evaluation and periprocedural management 59
Duration of Dual Antiplatelet Therapy for Patients at High Bleeding Risk Undergoing PCI 58
Impact of anemia on short-term outcomes after TAVR: A subgroup analysis from the BRAVO-3 randomized trial 58
Guided and unguided de-escalation from potent P2Y12 inhibitors among patients with acute coronary syndrome: a meta-analysis 57
A sex paradox in clinical outcomes following complex percutaneous coronary intervention 57
Platelets and the Atherosclerotic Process: An Overview of New Markers of Platelet Activation and Reactivity, and Their Implications in Primary and Secondary Prevention 57
Impact of renal function in high bleeding risk patients undergoing percutaneous coronary intervention: a patient-level stratified analysis from four post-approval studies 56
Evolution of drug-eluting coronary stents: a back-and-forth journey from the bench-to-bedside 56
Assessing the risk of acute kidney injury after primary PCI: The simpler the sooner the better 56
3- or 1-Month DAPT in Patients at High Bleeding Risk Undergoing Everolimus-Eluting Stent Implantation 55
Prognostic Value of Baseline Inflammation in Diabetic and Nondiabetic Patients Undergoing Percutaneous Coronary Intervention 54
Impact of Small Valve Size on 1-Year Outcomes After Transcatheter Aortic Valve Implantation in Women (from the WIN-TAVI Registry) 54
Residual SYNTAX Score and One-Year Outcome in Elderly Patients With Acute Coronary Syndrome 54
Bleeding and Ischemic Outcomes With Ticagrelor Monotherapy According to Body Mass Index 54
Ticagrelor Monotherapy Versus Dual-Antiplatelet Therapy After PCI: An Individual Patient-Level Meta-Analysis 53
Edge-to-edge percutaneous mitral repair for functional ischaemic and non-ischaemic mitral regurgitation: a systematic review and meta-analysis 53
Prognostic Impact of High-Sensitivity C-Reactive Protein in Patients Undergoing Percutaneous Coronary Intervention According to BMI 53
Effect of Elevated C-Reactive Protein on Outcomes After Complex Percutaneous Coronary Intervention for Angina Pectoris 52
Impact of target vessel choice on outcomes following percutaneous coronary intervention in patients with a prior coronary artery bypass graft 51
Revascularization in patients with valvular heart disease 51
Sex-Related Differences in Patients at High Bleeding Risk Undergoing Percutaneous Coronary Intervention: A Patient-Level Pooled Analysis From 4 Postapproval Studies 51
PROGNOSTIC VALUE OF HIGH-SENSITIVITY C-REATIVE PROTEIN AMONG CHRONIC KIDNEY DISEASE PATIENTS UNDERGOING PERCUTANEOUS CORONARY INTERVENTION 51
Incidence, predictors and impact of stroke on mortality among patients with acute coronary syndromes following percutaneous coronary intervention-Results from the PROMETHEUS registry 50
Clinical outcomes after TAVR with heparin or bivalirudin as periprocedural anticoagulation in patients with and without peripheral arterial disease: Results from the BRAVO-3 randomized trial 50
Validation of the Academic Research Consortium High Bleeding Risk Definition in Contemporary PCI Patients 50
Dual antiplatelet therapy duration after percutaneous coronary intervention in high bleeding risk: a meta-analysis of randomized trials 49
Incidence, predictors and clinical impact of permanent pacemaker insertion in women following transcatheter aortic valve implantation: Insights from a prospective multinational registry 48
Efficacy and Safety of P2Y12 Inhibitor Monotherapy After Complex PCI: A Collaborative Systematic Review and Meta-Analysis 48
Clopidogrel Monotherapy After 1-Month DAPT in Diabetic Patients Undergoing PCI: Is Less Always More? 48
ARC-HBR criteria and TAVR: not all high bleeding risk patients look alike 47
Prevalence and Impact of High Bleeding Risk in Patients Undergoing Left Main Artery Disease PCI 47
Reversal and removal of oral antithrombotic drugs in patients with active or perceived imminent bleeding 47
Types of myocardial injury and mid-term outcomes in patients with COVID-19 46
Lipid Management in Patients Presenting With Acute Coronary Syndromes: A Review 46
The mega COMBO collaboration: An individual patient data pooled analysis of patients undergoing PCI with COMBO stent 46
Perioperative risk and antiplatelet management in patients undergoing non-cardiac surgery within 1 year of PCI 46
Pericardial Effusion Provoking Atrial Fibrillation After Cardiac Surgery: JACC Review Topic of the Week 46
One-Month Versus Three-Month Dual-Antiplatelet Therapy in High Bleeding Risk Patients With Chronic Kidney Disease 45
Treating Inflammation Prior to Percutaneous Coronary Intervention: Does the Heart Care? 45
Sex-Related Outcomes of Medical, Percutaneous, and Surgical Interventions for Coronary Artery Disease: JACC Focus Seminar 3/7 45
Ticagrelor Monotherapy After PCI in High-Risk Patients With Prior MI: A Prespecified TWILIGHT Substudy 45
Preprocedural anemia in females undergoing transcatheter aortic valve implantation: Insights from the WIN-TAVI registry 44
Ticagrelor monotherapy in patients with chronic kidney disease undergoing percutaneous coronary intervention: TWILIGHT-CKD 44
Prevalence and prognostic impact of hsCRP elevation are age-dependent in women but not in men undergoing percutaneous coronary intervention 43
New Criteria to Identify Patients at Higher Risk for Cardiovascular Complications After Percutaneous Coronary Intervention 43
Predictors of antiplatelet cessation in a real-world patient population undergoing non-cardiac surgery after PCI 43
Impact of Age on the Safety and Efficacy of Ticagrelor Monotherapy in Patients Undergoing PCI 42
The impact of chronic kidney disease in women undergoing transcatheter aortic valve replacement: Analysis from the Women's INternational Transcatheter Aortic Valve Implantation (WIN-TAVI) registry 42
Safety and efficacy of ticagrelor monotherapy according to drug-eluting stent type: the TWILIGHT-STENT study 42
Clinical and procedural outcomes of percutaneous coronary intervention for de novo lesions involving the ostial left circumflex coronary artery 41
Impact of diabetes mellitus on short term vascular complications after TAVR: Results from the BRAVO-3 randomized trial 41
Ticagrelor Monotherapy After Coronary Stenting: Is the GLASS Half Full or Half Empty? 41
P2Y12 Inhibitor or Aspirin Monotherapy for Secondary Prevention of Coronary Events 40
Vitamin D and Cardiovascular Diseases: From Physiology to Pathophysiology and Outcomes 40
Recent Advances in Antiplatelet Therapy in Complex Percutaneous Coronary Intervention 40
Management of Adults With Anomalous Aortic Origin of the Coronary Arteries: State-of-the-Art Review 39
Impact of diabetes mellitus on female subjects undergoing transcatheter aortic valve implantation: Insights from the WIN-TAVI international registry 39
Perioperative Management of P2Y12 Inhibitors in Patients Undergoing Cardiac Surgery within 1 Year of PCI 39
Minding the Microcirculation: Is it Worth the Effort? 38
From surgical clamping to endovascular flow arrest/reversal: the concept behind the system 38
Rethinking the Role of Impaired Renal Function in Multivessel PCI or CABG 38
Ticagrelor monotherapy after PCI in patients with concomitant diabetes mellitus and chronic kidney disease: TWILIGHT DM-CKD 38
Ticagrelor in Patients With Cancer: 2 Birds With 1 Stone 37
Uninterrupted direct-acting oral anticoagulation in patients undergoing transradial percutaneous coronary procedures: The DOAC-NOSTOP study rationale and design 37
Dyspnea-Related Ticagrelor Discontinuation After Percutaneous Coronary Intervention 37
Stick to the guidelines or clinical judgment: A toss up? 37
Ticagrelor With or Without Aspirin in High-Risk Patients With Anemia Undergoing Percutaneous Coronary Intervention: a subgroup analysis of the TWILIGHT trial 37
Impact of sex on long-term cardiovascular outcomes of patients undergoing percutaneous coronary intervention for acute coronary syndromes 36
Sex-Related Differences in the Prevalence and Prognostic Value of the Academic Research Consortium for High Bleeding Risk Criteria 36
Periprocedural anticoagulation in non-ST-segment elevation acute coronary syndrome: time to reassess? 36
Sodium Bicarbonate, Contrast-Associated Acute Kidney Injury, and Long-Term Outcomes: The End of an Era? 35
Predictive value of the thrombotic risk criteria proposed in the 2023 ESC guidelines for the management of ACS: insights from a large PCI registry 34
Left Atrial Appendage Closure Compared With Oral Anticoagulants for Patients With Atrial Fibrillation: A Systematic Review and Network Meta-Analysis 34
Subjective angina or myocardial ischaemia to justify PCI? Never mistake the finger for the moon 34
SGLT-2 inhibitors and cardiovascular outcomes in patients with and without a history of heart failure: a systematic review and meta-analysis 34
Performance of the academic research consortium high-bleeding risk criteria in patients undergoing PCI for acute myocardial infarction 32
Thrombotic risk in patients with acute coronary syndromes discharged on prasugrel or clopidogrel: results from the PROMETHEUS study 31
First and recurrent events in the ISCHEMIA trial: two sides of the same coin 31
Long-Term Ticagrelor in Stable Patients With Prior Myocardial Infarction: Bleeding Avoidance First and Foremost 30
Totale 5.712
Salva come PNG Salva come JPEG
Categoria #
all - tutte 36.497
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 36.497
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202110 0 0 0 0 0 0 0 0 0 0 0 10
2021/202257 3 2 0 13 2 1 0 6 5 2 15 8
2022/2023487 21 5 13 43 33 30 77 27 92 99 38 9
2023/2024686 69 51 152 37 12 84 51 14 23 37 81 75
2024/20251.095 22 3 17 11 19 139 70 83 198 282 137 114
2025/20263.477 407 294 539 241 127 150 886 219 164 215 112 123
Totale 5.903